Clinical trials: Gastrointestinal and Digestive Disorder
Hepatocellular Carcinoma (HCC)
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
In this single-center, single-arm, prospective, open-label Phase 1/2 study, the safety and efficacy of autologous GPC3-targeted chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients with GPC3-positive…
- Trial name
- NCT06641453
- Testing
- GPC3-CART cells, Fludarabine Phosphate for Injection, Cyclophosphamide for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Pharynx Cancer, Larynx Cancer
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
Randomized multicenter trial to assess the impact of a screening program for heavy alcohol drinkers and smokers treated in alcohol addiction clinics on upper aerodigestive tract cancer mortality.
- Conditions
- Pharynx Cancer, Larynx Cancer, Oral Cavity Cancer, Oesophageal Cancer
- Trial name
- NCT00359645
- Testing
- Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years
- Where
- 35 sites in France
- Volunteers
- 1,993 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
Cancer of Pancreas
Pancreatico Enteric Anastomosis Post Pancreaticoduodenectomy
The aim of this study is to make a step for evaluation and presentation of a safe technique for pancreatico-jejunostomy that help in minimizing post-operative morbidity and mortality in pancreatic cancer patient by comparing…
- Trial name
- PEAPP (NCT05163977)
- Testing
- Blumgart Anastomosis, Cattell Warren Anastomosis
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Peritoneal Neoplasms
Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin
Objectives: The overall objective of this prospective study is to provide a descriptive analysis of the quality of life of cancer patients enrolled on M. D.
- Trial name
- NCT00502177
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced…
- Trial name
- NCT06359275
- Testing
- PD-1, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC)
Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
This single-center prospective observational cohort study aims to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line…
- Trial name
- NCT07734857
- Testing
- No intervention (observational study)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
PTSD
Glecaprevir/Pibrentasvir for the Treatment of PTSD
An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the…
- Trial name
- NCT05446857
- Testing
- Glecaprevir / Pibrentasvir Pill
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- White River Junction Veterans Affairs Medical Center
Biliary Tract Cancer (BTC)
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).
- Trial name
- NCT06622057
- Testing
- D07001-Softgel Capsules, Capecitabine
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 240 people
- Sponsor
- InnoPharmax Inc.
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma
- Trial name
- NCT01260701
- Testing
- Akt Inhibitor MK2206
- Where
- 187 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Functional Status
Functional and Respiratory Predictors of Early Postoperative Outcomes
Functional status is a fundamental indicator reflecting a patient's ability to perform activities of daily living and is closely associated with early postoperative outcomes.
- Conditions
- Colorectal Cancer, Functional Status, Respiratory Parameters, Clinical Outcomes
- Trial name
- NCT07529301
- Testing
- Preoperative Assessments, Postoperative Assessments (Daily from Postoperative Day 1 Until Discharge)
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Müşerref Ebru YALÇIN
Crohn's Disease
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD)…
- Trial name
- INFORM (NCT00707512)
- Testing
- natalizumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Biogen
Inflammatory Bowel Diseases
Folic Acid in Pediatric Inflammatory Bowel Disease
Inflammatory bowel disease often requires immunomodulators, such as methotrexate, to maintain disease remission. This medication is administered as one dose weekly.
- Trial name
- NCT03860012
- Testing
- Folic Acid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Le Bonheur Children's Hospital
Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years.
- Trial name
- GLUCORRECTOR (NCT03512119)
- Testing
- Lumacaftor-Ivacaftor treatment
- Where
- 13 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Pancreatic Cancer
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
This is an open multicenter randomized phase I/II study. The main purpose with this study is to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus given biweekly to patients with local advanced…
- Trial name
- NCT01042028
- Testing
- Everolimus, Cetuximab, Irinotecan, Capecitabine, Oxaliplatine
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Per Pfeiffer
Hemorrhoids, Haemorrhoids
Effect of Early Warm Water Sitz Bath on Urinary Retention After Hemorrhoidectomy
Background: Hemorrhoid is one of the most common chronic anorectal diseases. The prevalence rate is about 44%. It occurs in adults aged 45-65 years.
- Conditions
- Hemorrhoids, Haemorrhoids, Piles, Hemorrhoidal Disease
- Trial name
- NCT04535765
- Testing
- early warm water sitz bath, Regular time warm water sitz bath
- Where
- Taiwan
- Volunteers
- 64 people
- Sponsor
- Cathay General Hospital
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
This study will evaluate the effect of CPAP therapy on esophageal pH and lung inflammation in patients with idiopathic pulmonary fibrosis (IPF) and sleep apnea.
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Gastro Esophageal Reflux
- Trial name
- NCT05359965
- Testing
- Positive Airway Pressure
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Rectal Cancer
Chinese Surgical Robot Clinical Study on Rectectomy for Rectal Cancer
Central South University in collaboration with Tianjin University developed the first domestically produced Chinese minimally invasive surgical (MIS) robot system which named "Micro Hand S" in 2013.
- Trial name
- NCT04836741
- Testing
- Micro Hand S robot, Laparoscope
- Where
- China
- Volunteers
- 105 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.